»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Pazopanib CAS 444731-52-6 Pazopanib Pazopanib base manufacturer

5th

Gold Index: 89140

You are here: home  > New products  > Pazopanib CAS 444731-52-6 Pazopanib Pazopanib base

Pazopanib CAS 444731-52-6 Pazopanib Pazopanib base 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: MOS 28
Production Capacity: 300kg/year
Delivery Date: ithin 7 days
Molecular Weight: 437.52
Content: 98%min
Boiling point: 728.8°C at 760 mmHg
Vapour pressure: 4.26E-21mmHg at 25°C
Means of Transport: Ocean,Land,Air
Packing: s per request of clients
Molecular Formula: C21H23N7O2S
Specification: CP/USP/EP
Brand: MOSINTER
Flashing point: 394.6°C

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits ang

Pazopanib (CAS: 444731-52-6)


Item

Index

Molecular Formula

C21H23N7O2S

Molecular Weight

437.52

Specification

CP/USP/EP

Content

98%min


Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.



Medical uses

It is approved by numerous regulatory administrations worldwide (including the FDA (19 October 2009), EMA (14 June 2010), MHRA (14 June 2010) andTGA (30 June 2010)) for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas. In Australia it is subsidised under the PBS, under a number of conditions, including:

  • The medication is used to treat clear cell variant renal cell carcinoma.

  • The treatment phase is continuing treatment beyond 3-months.

  • The patient has been issued an authority prescription for pazopanib

  • The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)

  • This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition.

  • It has also demonstrated initial therapeutic properties in patients with ovarian and non-small cell lung cancer, though plans to apply to the EMA for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country.

    Contraindications

    The only contraindication is hypersensitivity to pazopanib or any of its excipients. Cautions include:

  • Hypertension, including hypertensive crises reported

  • QT interval prolongation and torsades de pointes reported.

  • Thrombotic microangiopathy reported

  • Thrombotic thrombocytopenic purpura reported

  • Haemolytic uremic syndrome reported

  • Haematologic parameter alterations reported in 31-37% of patients.

  • Events of cardiac dysfunction (decreased LVEF and congestive heart failure) have been observed

  • Fatal haemorrhage, arterial and venous thrombotic events and GI perforation have been observed in randomized clinical trials.

  • It has one black box warning by the US FDA, severe hepatotoxicity, including fatalities.

    Adverse effects

    See also: List of adverse effects of pazopanib

    The most common side effects of pazopanib are nausea, vomiting, diarrhoea (occurs in about half of patients), changes in hair colour, hypertension (which usually occurs during the first few weeks of treatment), appetite loss, hyperglycaemia, hypoglycaemia, electrolyte abnormalities (includinghypocalcaemia, hypomagnesemia, hypophosphatemia), lab anomalies (including increased AST, ALT and protein in the urine), oedema, hair loss or discolouration, taste changes, abdominal pain, hypertension, rash, fatigue and myelosuppression (including leucopenia, neutropenia,thrombocytopenia and lymphopenia). It has been associated with a low, but real risk of potentially fatal liver damage.

    Overdose

    The treatment for overdose is purely supportive and the symptoms include grade 3 hypertension and fatigue.

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: